ArticleThe Prostate2026
Socioeconomic and Demographic Factors in Genetic Testing Utilization Among Advanced Prostate Cancer Patients.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeGermline genetic testing in patients with advanced prostate cancer (PCa) is underutilized and hypothesized to be impacted by socioeconomic and demographic factors. This single institution, retrospective study assessed the association of income and social vulnerability with genetic referrals and testing.
methodsThe Henry Ford Health (HFH) tumor registry was queried for new diagnoses of stage III, IV PCa from 2017 to 2022. 1385 patients were eligible and 186 patients (13.43%) received a referral, while 1199 (86.57%) patients did not. Median household income (gMHI) and social vulnerability index (SVI) were assigned based on census tract level geocoding and analyzed by tertiles. Univariable and multivariable logistic regression analyses were performed assessing referral for genetic counseling and completion of genetic testing as outcomes. In the multivariable analysis, associations between age, stage and gMHI were analyzed.
resultsBlack and stage IV patients were more likely to receive genetics referral than White and stage III patients, respectively (20.3% vs 10.6%, p < 0.0001; 25.5% vs 7.3%, p < 0.0001). Multivariable analysis showed that middle gMHI tertile patients had 53% lower unadjusted OR for genetic referral than lowest gMHI tertile patients (OR = 0.47, 95% CI [0.29, 0.75]; p = 0.0017). There was no significant difference in the odds of referral between the highest and lowest gMHI tertiles (OR = 1.22, 95% CI [0.83, 1.79]; p = 0.3175). No other significant associations were found between gMHI, SVI and genetic counseling referrals or completion of testing. Adjusted comparisons showed significant associations between increased referral or testing rate and decreasing age and more advanced stage (OR = 0.97, 95% CI [0.95, 1.00]; p = 0.0218), (OR = 2.84, 95% CI [1.70, 4.74]; p = 0.0001).
conclusionAlthough socioeconomic factors have been hypothesized as barriers to genetic testing, we found no evidence of an association in our patient population. Instead, the lowest gMHI tertile patients were equally as likely to complete genetic testing as highest gMHI tertile patients, indicating socioeconomic barriers can be overcome. Clinical factors including age and stage did independently predict completion of testing, supporting referral for testing based on clinical characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.